Healthcare Triangle, Inc.
For the period ended Mar 31, 2025. Filed May 20, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 20, 2025
HCTI$4.21-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(1,700) | $(1,862) |
| Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities | ||
| Depreciation & amortization | 12 | 536 |
| Interest expense settled by equity | 316 | - |
| Common stock issued for services | 88 | - |
| Amortization of debt discount | 223 | 36 |
| Other income | (111) | - |
| Stock compensation expenses | 36 | 26 |
| Changes in operating assets and liabilities: | ||
| (Increase)/ decrease in: | ||
| Accounts receivable | (797) | 1,141 |
| Other current assets | (785) | 486 |
| Due from affiliates | (1,448) | 271 |
| Accounts payable and accrued expenses | (820) | 60 |
| Other current liabilities | (572) | (744) |
| Net cash used in operating activities | (5,557) | (50) |
| Cash flows from investing activities | ||
| Net cash provided by/ (used in) investing activities | - | - |
| Cash flows from financing activities | ||
| Increase/(decrease) in short term borrowing | 186 | (883) |
| Repayment of convertible note | (1,500) | - |
| Proceeds from equity issuance (Note 8) | 13,677 | - |
| Net cash provided by/ (used in) financing activities | 12,363 | (883) |
| Net increase (decrease) in cash and cash equivalents | 6,806 | (933) |
| Cash and cash equivalents | ||
| Cash and cash equivalents at the beginning of the period | $20 | $1,234 |
| Cash and cash equivalents at the end of the period | $6,826 | $301 |
| Non-cash investing and financing activities | ||
| Supplementary disclosure of cash flows information | ||
| Interest | 413 | 149 |
| Conversion of debt to equity | 1,191 | - |
The accompanying notes are an integral part of these condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.